Skip to main content

Sirna Therapeutics Sees Revenues Dwindle, Losses Widen in Q1

NEW YORK, April 29 (GenomeWeb News) - Sirna Therapeutics reported decreased revenues and widening losses for the first quarter on Tuesday.

 

Revenues for the quarter totaled $318,000, down from $490,000 for the year-ago period.

 

R&D expenses for the first quarter were $5.1 million, up from $3.8 million during the same quarter last year.

 

The company's net loss was $5.9 million, or $.19 per share, up from $4.9 million, or $1.62 per share, for the same period last year.

 

As of March 31, Sirna, based in Boulder, Colo., had $29.6 million in cash, cash equivalents, and securities.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.